CompletedNCT05473702

Smart Textile Sensor System for Health Monitoring

Sponsor: Nanowear Inc.

Trial Details

Condition	Heart Disease Chronic, Pulmonary Disease, Chronic Obstructive, Blood Pressure, Heart Rhythm Disorder
Intervention	Nanowear SimpleSense Wearable monitoring device
Status	Completed
Participants	334
Est. Completion	31 Mar 2026
Last Updated	7 Apr 2026

Primary Outcome

Efficacy against gold standard devices; Efficacy against gold standard devices; Efficacy against gold standard devices; Efficacy against gold standard devices

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * Healthy subject with no pre-existing conditions. * Subject with prehypertension * Subject with hypertension * Subject undergoing dialysis Exclusion Criteria: * Pregnant women * Subjects with implantable cardiac devices (for example, pacemaker or internal cardioverter defibrillator). * Subjects with arrhythmia.

Trial Sites

Countries

United States

View Registry Entry

Related Analysis

FDA-Approved Smart Textile Sensor System Shows Promise for Continuous Cardiac Monitoring — Results from 334-Patient Validation Study

A completed 334-patient validation study demonstrates the efficacy of FDA-approved smart textile sensors for continuous cardiac monitoring. The Nanowear SimpleSense system showed promise for real-time ECG, heart sounds, and impedance monitoring across diverse patient populations.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service